消息面上，兴齐眼药发布的2025年度向特定对象发行股票预案显示，公司拟募集资金不超过(含)8.5亿元，扣除发行费用后的募集资金净额全部投资于研发中 心建设项目及补充流动资金，拟分别投入募资额6.5亿元、2亿元。 兴齐眼药表示，通过本次募投项目的实施，公司将打造国际视野的综合型研发总部，全面提升公司的研发实力，拓宽公司产品管线，优化公司现有产品结 构，突破技术壁垒，通过差异化创新形成竞争优势，为公司带来新的利润增长点。 这是兴齐眼药时隔四年再度进行定增募资。在2020年9月，兴齐眼药曾发布2020年度向特定对象发行A股股票预案，在最初的预案中，公司拟定增募资不超8 亿元。 值得一提的是，兴齐眼药此次定增募资的募投项目，与2020年的募投项目出现重合，均包含研发中心建设项目。 具体来看，此次预案显示，研发中心建设项目总投资金额9.84亿元，其中前次募集资金投入金额为2.08亿元，本次募集资金拟投入6.5亿元。目前本项目已启 动建设，计划于2027年底前建设完成。 抛出定增募资计划后，5月28日，兴齐眼药（300573）遭到了投资者"用脚投票"。 交易行情显示，5月28日，兴齐眼药低开2.5%，开盘后，公司股价不断 ...

Core Viewpoint - Shenyang Xingqi Eye Pharmaceutical Co., Ltd. plans to raise up to 850 million yuan through a private placement to enhance R&D innovation and strengthen its market position in the ophthalmic drug sector [1][5] Group 1: Financial Performance - Since its listing in December 2016, the company's revenue has grown from 339 million yuan in 2016 to 1.943 billion yuan in 2024, representing a nearly sixfold increase with a compound annual growth rate (CAGR) of 24.39% [2] - Net profit increased from 54.28 million yuan in 2016 to 338 million yuan in 2024, also showing over sixfold growth and a CAGR of 25.69% [2] - In Q1 of the current year, the company achieved a revenue of 536 million yuan, a year-on-year increase of 53.24%, and a net profit of 146 million yuan, which is more than three times the previous year [2] Group 2: R&D Investment and Strategy - The company maintains a high R&D intensity, with R&D expenditure reaching 235 million yuan in 2024, accounting for 12.11% of its revenue [4] - The planned R&D center aims to create a benchmark in the ophthalmic field, integrating smart laboratory systems, international R&D collaboration, and innovation platforms [4][5] - The implementation of the fundraising project is expected to enhance the company's R&D capabilities, broaden its product pipeline, and optimize existing product structures, ultimately driving sustainable growth [5] Group 3: Competitive Advantage - The company has established a strong competitive advantage in the ophthalmic drug sector due to its focus on R&D and continuous high investment in innovation [3] - The diverse product line covers various common eye diseases, contributing to the company's robust market position [3]

Core Viewpoint - The company plans to issue shares to specific investors in 2025, raising up to 850 million yuan, which may dilute immediate returns for existing shareholders [2][3][8]. Group 1: Financial Impact of Share Issuance - The total number of shares before the issuance is 245,348,945, and the maximum number of shares to be issued is 73,604,683, which represents up to 30% of the pre-issuance total [2][3][6]. - The projected net profit for 2025, assuming no growth, is estimated to remain at 347,542,460 yuan, leading to a basic earnings per share (EPS) of 1.38 yuan post-issuance [6][7]. - Under three scenarios of net profit growth (0%, 10%, and 20%), the diluted EPS and return on equity (ROE) will decrease post-issuance, indicating a potential dilution of shareholder returns [6][7][8]. Group 2: Necessity and Reasonableness of the Issuance - The funds raised will be allocated to the construction of a research and development center and to supplement working capital, aligning with the company's strategic direction and industry trends [9][10]. - The issuance is deemed necessary to enhance the company's R&D capabilities and improve its financial structure, which is expected to strengthen its competitive position in the market [9][10][11]. Group 3: Measures to Mitigate Dilution of Returns - The company plans to implement measures to counteract the dilution of immediate returns, including enhancing core business operations and improving fund management [9][11]. - Commitments from major stakeholders, including the controlling shareholder and management, have been made to ensure the effectiveness of these measures and to protect shareholder interests [12][13].

Fundraising Plan - The company plans to raise a total of no more than 850 million yuan, with the net amount after deducting issuance costs to be used entirely for project construction [1] - The total investment for the projects exceeds the net amount raised, with the company planning to cover the shortfall through self-funding or other financing methods [1] Necessity and Feasibility of Fundraising - The R&D center construction project is a continuation of a previous fundraising initiative, aimed at addressing a funding gap to ensure smooth project development [2][3] - The project aims to establish a comprehensive R&D headquarters with international vision, focusing on intelligent, digital, and international research capabilities [2] Project Details - The total investment for the R&D center is 984.23 million yuan, with 207.97 million yuan already invested from previous fundraising efforts and 650 million yuan planned from the current fundraising [3][4] - The project will include advanced facilities such as a high-standard data center and automated systems to enhance research efficiency and data reliability [3] R&D Focus and Market Position - The company emphasizes the importance of R&D as a core driver for pharmaceutical development, with a focus on building a strong pipeline of innovative products [5][6] - Recent product launches, including a treatment for dry eye syndrome, have significantly contributed to revenue growth, with total revenue increasing from approximately 689 million yuan in 2020 to about 1.943 billion yuan in 2024 [5][6] Future R&D Directions - The company is expanding its product line in the ophthalmology sector, focusing on innovative treatments for various eye diseases, including age-related macular degeneration and diabetic macular edema [7][8] - The development of new treatment methods, including gene therapy, is seen as a key opportunity for the company to enhance its market position [7] Financial Impact of Fundraising - The fundraising will improve the company's liquidity and capital structure, enhancing its ability to manage risks and support sustainable growth [12][13] - The successful implementation of the fundraising projects is expected to strengthen the company's core competitiveness and long-term viability [13]

Core Viewpoint - The report provides a detailed account of the fundraising activities and the utilization of the raised funds by Shenyang Xingqi Eye Pharmaceutical Co., Ltd. as of December 31, 2024, highlighting the financial figures and project statuses [1][2][3]. Fundraising Overview - The company raised a total of RMB 599,669,492.10 through the issuance of 5,763,282 shares, with actual funds received amounting to RMB 581,870,425.73 after deducting underwriting fees [1][2]. - The funds were fully received by December 22, 2021, and verified by a certified public accountant [1]. Fund Utilization - As of December 31, 2024, the total amount of funds utilized was RMB 382,520,531.09, with remaining funds of RMB 195,077,792.24 held in a dedicated bank account [2][3]. - The company has not changed the investment projects but adjusted the implementation locations for certain projects, specifically the "R&D Center Construction" project [2][3]. Project Status and Economic Benefits - The "Single-Dose Production Line Construction" project is expected to achieve an internal rate of return of 51.96% and a net present value of RMB 904,582,400, with an anticipated annual revenue of RMB 1,970,283,200 once operational [4]. - The "R&D Center Construction and New Drug Development" project aims to enhance the company's R&D capabilities, although direct economic benefits cannot be quantified at this stage due to the nature of drug development processes [4]. Financial Summary - The total amount of funds raised was RMB 599,669,492.10, with cumulative usage amounting to RMB 399,868,000, indicating a significant portion of the funds has been allocated to various projects [3][4]. - The company has approved the permanent allocation of surplus funds to supplement working capital, reflecting a strategic financial management approach [2][3].

Meeting Announcement - The company will hold its first extraordinary general meeting of shareholders in 2025 on June 13, 2025, at 14:30 [1] - The meeting will be conducted both in-person and via online voting [2] Voting Procedures - Shareholders can vote in person or authorize a representative to attend the meeting [2] - Online voting will be available through the Shenzhen Stock Exchange trading system and internet voting system from 9:15 to 15:00 on June 13, 2025 [2][5] Agenda Items - The meeting will discuss several proposals, including the plan for issuing A-shares to specific targets for the year 2025 [3][4] - All proposals require a two-thirds majority approval from attending shareholders [4] Registration Details - Shareholders must register to attend the meeting, with specific requirements for both corporate and individual shareholders [4][5] - Registration can also be done via mail, fax, or email for remote shareholders [4][5] Contact Information - The company has provided contact details for inquiries related to the meeting [5]

Core Viewpoint The company, Shenyang Xingqi Eye Pharmaceutical Co., Ltd., has approved a plan to issue A-shares to specific investors, aiming to raise up to 850 million yuan for various projects, subject to shareholder approval and regulatory compliance. Group 1: Board Meeting and Resolutions - The board meeting was conducted via electronic means, and all members were notified of the meeting details [1] - The board approved the proposal for the company to issue A-shares to specific investors, confirming compliance with relevant laws and regulations [2][3] - The voting results for all resolutions were unanimous, with 9 votes in favor and no opposition [1][2][3] Group 2: Issuance Details - The issuance will consist of domestic A-shares with a par value of 1 yuan each, targeting no more than 35 specific investors [2][3] - The pricing will be set at no less than 80% of the average trading price over the 20 trading days prior to the pricing date [4] - The total amount raised from the issuance will not exceed 850 million yuan, with the number of shares issued capped at 30% of the total shares before the issuance [5][6] Group 3: Fund Utilization and Project Investment - The net proceeds from the issuance will be fully invested in specific projects, with a total investment amounting to 1.184 billion yuan, of which 850 million yuan will come from the issuance [6][7] - If the actual funds raised are less than planned, the company will adjust the investment amounts based on project importance and urgency [7] Group 4: Shareholder Rights and Limitations - Shares acquired through this issuance will be subject to a six-month lock-up period post-issuance [6] - The company's retained earnings will be shared proportionally among existing and new shareholders after the issuance [7] Group 5: Future Steps and Authorizations - The board will seek authorization from shareholders to manage the issuance process, including adjustments based on market conditions and regulatory requirements [12][13] - A temporary shareholder meeting is scheduled for June 13, 2025, to discuss the issuance and other related matters [15]

一、审议通过《关于公司符合向特定对象发行A股股票条件的议案》 经审议，独立董事认为，公司符合《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司证券发行注册管理办法》等法律法规、规范性文件关于向特定对 象发行A股股票的有关规定，具备向特定对象发行A股股票的条件。 沈阳兴齐眼药股份有限公司 第五届董事会独立董事专门会议 2025 年第二次会议决议 沈阳兴齐眼药股份有限公司（以下简称"公司"）第五届董事会独立董事专门 会议 2025 年第二次会议通知于会议召开前 3 日以电子邮件的形式发出，会议于 2025 年5月27 日在公司会议室以现场与通讯会议相结合的方式召开。公司独立董事共 3 人， 出席本次会议的独立董事共 3 人，会议由独立董事徐先梅女士召集并主持。本次会 议的召开符合《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 及《沈阳兴齐眼药股份有限公司章程》（以下简称"《公司章程》"）等有关规定， 会议形成的决议合法、有效。与会独立董事经认真讨论，形成如下决议： 独立董事一致同意该议案，并同意将本议案提交公司 ...

证券代码：300573 证券简称：兴齐眼药 沈阳兴齐眼药股份有限公司 SHENYANG XINGQI PHARMACEUTICAL CO., LTD. （中国（辽宁）自由贸易试验区沈阳片区新运河路 25 号） 2025 年度向特定对象发行股票 方案论证分析报告 二〇二五年五月 | 目 录 1 | | | --- | --- | | 释 2 | 义 | | 一、本次发行的背景和目的 4 | | | （一）本次发行的背景 4 | | | （二）本次发行的目的 5 | | | 二、本次发行证券及其品种选择的必要性 6 | | | （一）本次发行证券的品种 6 | | | （二）本次发行证券品种选择的必要性 6 | | | 三、本次发行对象的选择范围、数量和标准的适当性 7 | | | （一）本次发行对象选择范围的适当性 7 | | | （二）本次发行对象数量的适当性 7 | | | （三）本次发行对象标准的适当性 8 | | | 四、本次发行定价的原则、依据、方法和程序的合理性 8 | | | （一）本次发行定价的原则和依据 8 | | | （二）本次发行定价的方法和程序 9 | | | 五、本次发行方式的可行性 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-023 沈阳兴齐眼药股份有限公司 关于 2025 年度向特定对象发行股票 预案披露的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）于 2025 年 5 月 27 日召开 了第五届董事会第九次会议和第五届监事会第九次会议，审议通过了《关于公司 2025 年度向特定对象发行股票预案的议案》。《沈阳兴齐眼药股份有限公司 2025 年度向特定对象发行股票预案》及相关文件于中国证监会指定的创业板信息披露 网站巨潮资讯网（http://www.cninfo.com.cn）上披露，敬请投资者注意查询。 公司2025年度向特定对象发行股票预案的披露事项不代表审批机关对本次 发行股票相关事项的实质性判断、确认或批准。本预案所述本次向特定对象发行 股票相关事项的生效和完成尚待公司股东大会通过、深圳证券交易所审核通过并 经中国证监会作出同意注册决定。敬请广大投资者注意投资风险。 特此公告。 沈阳兴齐眼药股份有限公司 董事会 2025 年 5 月 27 日 1 ...